Congestive heart failure: Difference between revisions
Jump to navigation
Jump to search
| Line 40: | Line 40: | ||
==Treatment== | ==Treatment== | ||
====[[Congestive heart failure invasive monitoring|Invasive Hemodynamic Monitoring]]==== | ====[[Congestive heart failure invasive monitoring|Invasive Hemodynamic Monitoring]]==== | ||
| Line 46: | Line 45: | ||
====Medical Therapy:==== | ====Medical Therapy:==== | ||
: '''[[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]]''' | : '''[[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]]''' | ||
: '''Chronic Pharmacotherapy:''' [[Congestive heart failure diuretics|Diuretics]] | [[Congestive heart failure ACE inhibitors or angiotensin receptor blockers|ACE Inhibitors]] | [[Congestive heart failure ACE inhibitors or angiotensin receptor blockers|Angiotensin receptor blockers]] | [[Congestive heart failure aldosterone antagonists|Aldosterone Antagonists]] | [[Congestive heart failure | : '''Chronic Pharmacotherapy:''' [[Congestive heart failure diuretics|Diuretics]] | [[Congestive heart failure ACE inhibitors or angiotensin receptor blockers|ACE Inhibitors]] | [[Congestive heart failure ACE inhibitors or angiotensin receptor blockers|Angiotensin receptor blockers]] | [[Congestive heart failure aldosterone antagonists|Aldosterone Antagonists]] | [[Congestive heart failure beta blockers|Beta Blockers]] | [[Congestive heart failure calcium channel blockers|Ca Channel Blockers]] | [[Congestive heart failure vasodilators|Nitrates]] | [[Congestive heart failure vasodilators|Hydralazine]] | [[Congestive heart failure positive inotropics|Positive Inotropics]] | [[Congestive heart failure anticoagulants|Anticoagulants]] | [[Congestive heart failure antiarrhythmic Drugs|Antiarrhythmic Drugs]] | [[Congestive heart failure other pharmacotherapies#Metformin|Metformin]] | [[Congestive heart failure other pharmacotherapies#Nutritional Supplements|Nutritional Supplements]] | [[Congestive heart failure other pharmacotherapies#Hormonal Therapies|Hormonal Therapies]] | ||
====[[Congestive heart failure and exercise|Exercise Training]]==== | |||
====Surgical Therapy:==== | ====Surgical Therapy:==== | ||
Revision as of 16:58, 6 April 2012
For patient information click here
| Heart failure | |
| ICD-10 | I50.0 |
|---|---|
| ICD-9 | 428.0 |
| DiseasesDB | 16209 |
| MedlinePlus | 000158 |
| MeSH | D006333 |
| Congestive Heart Failure Microchapters |
|
Pathophysiology |
|---|
|
Differentiating Congestive heart failure from other Diseases |
|
Diagnosis |
|
Treatment |
|
Medical Therapy: |
|
Surgical Therapy: |
|
ACC/AHA Guideline Recommendations
|
|
Specific Groups: |
|
Congestive heart failure On the Web |
|
Risk calculators and risk factors for Congestive heart failure |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Atif Mohammad, M.D.
Synonyms and Related Key Words: CHF, pump failure, left heart failure, right heart failure, chronic heart failure, acute heart failure, flash pulmonary edema, congestion, systolic dysfunction, LV dysfunction, LV failure, impaired filling, reduced cardiac output, pulmonary edema
Overview
Classification
Pathophysiology
Systolic dysfunction | Diastolic dysfunction
Epidemiology and Demographics
Causes
Risk Factors
Differential Diagnosis
Natural history, complications & prognosis
Diagnosis
Clinical Assessment | History & Symptoms | Physical Examination | Lab Tests | Electrocardiogram | Chest X Ray | Echocardiography | Exercise Stress Test | Myocardial Viability Studies | Cardiac Catheterization | Endomyocardial biopsy
Treatment
Invasive Hemodynamic Monitoring
Medical Therapy:
- Acute Pharmacotherapy
- Chronic Pharmacotherapy: Diuretics | ACE Inhibitors | Angiotensin receptor blockers | Aldosterone Antagonists | Beta Blockers | Ca Channel Blockers | Nitrates | Hydralazine | Positive Inotropics | Anticoagulants | Antiarrhythmic Drugs | Metformin | Nutritional Supplements | Hormonal Therapies
Exercise Training
Surgical Therapy:
- Biventricular Pacing or Cardiac Resynchronization Therapy (CRT) | Implantation of Intracardiac Defibrillator | Ultrafiltration | Left Ventricular Assist Devices (LVADs) | Cardiac Transplantation | Cardiac Surgery
Guideline Recommendations
Hospitalized Patients
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Implementation of Practice Guidelines
End-Of-Life Considerations
Specific Groups
Special Populations | Patients who have concomitant disorders | Obstructive Sleep Apnea in the Patient with CHF
Guidelines Resources
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]
- 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [2]
References
- ↑ Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (12):e154-235. DOI:10.1161/CIRCULATIONAHA.105.167586 PMID: 16160202
- ↑ Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID: 19324967